Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma or marginal zone lymphoma
MOH_2021-04-11_009841Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) comparing Tafasitamab + rituximab + lenalidomide with Placebo + rituximab + lenalidomide (2 arms). Primary endpoints: Progression-free survival in follicular lymphoma population and Progression-free survival in overall population. Started Mar 2021; status: recruiting.
02
Drugs
tafasitamab
03
Conditions
follicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on MOH_2021-04-11_009841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-04-11_009841.